N	Concordance
1	 After induction therapy (see above), a maintenance therapy is standard option o
2	igh rate of relapse with TSEB, adjuvant maintenance therapy with PUVA alone or c
3	tenance therapy versus interferon  alfa maintenance therapy alone in patients wi
4	ients in relation to disease status and maintenance therapy with interferon-alph
5	encing hematologic response will begin  maintenance therapy consisting of amifos
6	n of 6 mg/kg aminophylline, followed by maintenance therapy at a dose of 2 mg/kg
7	effective, all patients eventually die. Maintenance therapy will interferon-alph
8	cipients. Patients received triple-drug maintenance therapy with CsA, imuran and
9	administration of mercaptopurine during maintenance therapy improves the diseas
10	 eligible for the randomized trial for  maintenance therapy if the following con
11	ar residual disease at the beginning of maintenance therapy indicates poor outco
12	ostic factors.  The average duration of maintenance therapy for ALL ranges betw
13	ymptom relief, prevention of relapse on maintenance therapy and cost-effectivene
14	lected. The patients had been receiving maintenance therapy with aqueous ragweed